MedImmune: A Booster Shot for Astra?
Vaccine maker MedImmune (MEDI) was the latest prize for a big pharma looking to beef up its product offerings. Anglo-Swedish giant AstraZeneca (AZN) said Apr. 23 it would snap up the U.S. biotech for $15.2 billion, or $58 per share. MedImmune shares soared on the news to trade up 18% to close at $56.57 in Nasdaq trading Apr. 23.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.